Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Repligen (RGEN)

Repligen Q3 revenue up 11% to $209 million; GAAP loss on $41 million impairment

Mixed Impact 4 of 5 earnings

Repligen reported third-quarter 2026 revenue of $209.3 million, up 11% from $188.8 million a year earlier, and raised its full-year 2026 revenue guidance to $844 million-$852 million. The company swung to a GAAP loss of $0.68 per diluted share, driven by a $41.2 million intangible asset impairment charge, though adjusted EPS rose to $0.53 from $0.46.

Key points

  • Q3 revenue $209.3 million vs. $188.8 million a year earlier, up 11% as reported and 12.5% organic
  • GAAP loss per diluted share $0.68 vs. EPS of $0.26, including a $41.2 million intangible asset impairment charge
  • Adjusted diluted EPS $0.53 vs. $0.46; FY26 revenue guidance raised to $844 million-$852 million
  • BioLife Solutions acquisition closed October 6, 2026; cash and marketable securities $863 million at September 30, 2026

The filing

CompanyRepligen (RGEN)
Form8-K, current report
Filed with the SECOct 27, 2026, 7:04 AM ET
Accession number0001628280-26-067405

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 7, 2026, 11:17 PM ET, from the text of the filing and its press-release exhibits only.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.